Evaxion to Develop Novel Personalized Cancer Vaccines Using AI-Unearthed Targets
Evaxion Biotech, a pioneering clinical-stage TechBio company, specializes in developing AI-Immunology™ powered vaccines. Recently, the company announced an enhanced dedication to crafting tailored cancer vaccines by focusing on a new class of AI-discovered tumor antigens called Endogenous Retroviruses (ERVs). This innovative approach aims to widen the scope of cancer vaccine applicability, particularly for patients resistant to traditional cancer immunotherapy.
ERVs, remnants of ancient viruses embedded in our genome, are frequently overexpressed in cancerous cells but remain dormant in healthy tissue. This distinct feature renders them visible to the immune system and thus promising targets for cancer vaccines. Evaxion employs AI-Immunology™ to pinpoint therapeutically significant ERV tumor antigens from genomic data extracted from patient tumors.
AI-Immunology™ stands as a scalable and adaptable AI platform driving vaccine discovery for infectious diseases and cancers alike. By integrating exclusive AI models like PIONEER™, EDEN™, RAVEN™, and ObsERV™, the platform effectively simulates the intricacies of the patient's immune response. Through advanced computational modeling, AI-Immunology™ rapidly identifies, predicts, and designs vaccine candidates, revolutionizing immunotherapy by offering a comprehensive and personalized approach to combat evolving pathogens and malignant cells.
Evaxion's commitment to leveraging AI in immunotherapy marks a significant stride in cancer treatment, promising a more precise and effective approach to addressing the complexities of cancer biology while ushering in a new era of personalized medicine.
